Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing

Latham & Watkins represented Arcutis in the transaction.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that it…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now